Cargando…
Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
Sotorasib (LUMAKRAS™ in the USA and LUMYKRAS™ in the EU) is an orally active, first-in-class G12C-mutant KRAS (KRAS(G12C)) inhibitor. By binding irreversibly to KRAS(G12C), sotorasib inhibits downstream signalling pathways which are associated with cell growth and differentiation. Sotorasib is indic...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715446/ https://www.ncbi.nlm.nih.gov/pubmed/36315377 http://dx.doi.org/10.1007/s11523-022-00922-w |